From Bedside to Biosecurity: Managing Select Agents in Acute Care

As infection preventionists (IPs), we often joke that the craziest things we navigate tend to be late on a Friday afternoon before a holiday weekend. It is, therefore, only fitting that this is where our story begins.

It’s 4:17 PM on a Friday when your phone rings. The Emergency Department charge nurse sounds tense: “We have a 38-year-old postal worker with fever and bilateral forearm lesions. He mentioned helping clean up after some kind of incident at his facility last week—not white powder, so it was dismissed. What’s our protocol for specimen collection?”

Know Your Enemy: From Clinical Concern to Biosecurity Threat

In the world of health care, we are trained to see a pathogen as a potential cause of disease and to focus on healing the patient. We are trained to focus on the risks posed by the pathogen to staff and other patients in the emergency department (ED) and to leverage infection prevention practices to protect patients and the environment from accidental exposure. However, when the “incident” involves a postal facility and a suspicious powder, the IP’s role shifts from biosafety to biosecurity. The moment we cannot exclude a bioterrorism incident, we are not just managing a patient and a clinical specimen; we are potentially responsible for a select agent, one that is not part of our day-to-day workflows.

The IP’s relationship with public health and our innate understanding of the chain of infection is the epidemiological lens that enables us to recognize that this may be an anthrax event, understand how it is transmitted, and begin creating a plan to recognize that a cutaneous lesion may not just be an infection. In this moment, the IP becomes a critical partner, using their relationships with public health to transition from a standard patient care plan to a comprehensive biosecurity response.

Pathogen Threat: Traditional Enemy vs “Wolf in Sheep’s Clothing”

The first thing you do is ask to speak with the treating physician to obtain their clinical judgment on the likely culprit. While your first thought may be anthrax, you need to align with the clinical team on their thinking. The first thought may be relief: Anthrax is not contagious and does not spread person to person, so standard precautions rather than transmission-based isolation are sufficient.¹ This means it is unlikely that a patient or staff exposure or outbreak investigation will be needed. By calmly communicating that the risk is limited to those with direct exposure to the source, not the patient, you prevent unnecessary “lockdown” in the ED and keep the focus on the task at hand. Then the attending physician gets on the phone and says anthrax is likely and would like to know the protocol to collect the specimen and get it to the lab.

There are 2 phone calls to make after you get off the phone, and you have reviewed your internal protocols and followed your notification protocols: (1) notify your laboratory that you have a potential cutaneous anthrax case, and (2) call public health.

But here’s where our story takes an unexpected turn. What if I told you there is a pathogen that looks exactly like anthrax to the clinician, presents with the same cutaneous lesions, and has the same bioterror potential, but your laboratory might dismiss it as a harmless contaminant?

The Bcbva Wildcard: When Your Enemy Wears a Disguise

You feel confident in your anthrax response protocols. But what if the threat isn’t what it appears to be? What if your laboratory staff’s trained instincts—designed to protect against overreaction to common contaminants—become a vulnerability?

Enter Bacillus cereus biovar anthracis (Bcbva), the pathogen that has fundamentally changed the biosecurity landscape. This organism is clinically indistinguishable from anthrax, causing identical cutaneous lesions and potentially fatal systemic disease. But here’s the twist that keeps biosecurity experts awake at night: Under the microscope, Bcbva looks exactly like B cereus, one of the most common laboratory contaminants we encounter daily.

Unlike traditional B anthracis, which is nonmotile and nonhemolytic, Bcbva is motile and hemolytic, characteristics that laboratory technologists have been trained to associate with the ubiquitous and harmless B cereus. The danger is clear: A laboratory technologist, following standard protocols, might observe motility or hemolysis and immediately dismiss the organism as environmental contamination, never suspecting they are handling a select agent capable of causing anthrax-like disease.^2,3

This is why your communication with the public health department becomes critical. When you make that call to notify them of a potential anthrax case, they have insights into variants such as Bcbva and can give you and your lab instructions that any Bacillus species, regardless of motility or hemolysis, requires further testing. This ensures a shared understanding that a “harmless contaminant” they might typically disregard could be a bioterror agent in disguise.

The Public Health Partnership: Your 24/7 Tactical Support

When facing a potential bioterror event, the public health department is not just a regulatory requirement––it is your expert tactical support system. Department personnel maintain relationships with Laboratory Response Network (LRN) laboratories, understand federal notification requirements, and can coordinate the complex logistics of secure specimen transport. Most importantly, they are available 24/7 for exactly these scenarios.

As you prepare for that 4:30 PM call to public health, have 3 key pieces of information ready:

1. Exposure history: Provide specific details about the postal facility incident. Was it a suspicious package? A powder release? Environmental contamination? The more detail you can provide about the potential exposure, the better public health can assess the threat level and coordinate appropriate response resources.

2. Clinical status: Describe the patient’s presentation in detail. Are the lesions consistent with cutaneous anthrax (painless, black eschar with surrounding edema)? Any signs of systemic illness? The clinical picture helps public health determine urgency and appropriate testing protocols.

3. Specimen status: Has the specimen been collected? Where is it currently located? Has it been processed or manipulated in any way? This information is crucial for maintaining the chain of custody and ensuring the specimen’s integrity for forensic analysis.

Public health coordinates with the LRN, specialized CDC laboratories equipped to safely handle and definitively identify bioterror agents through polymerase chain reaction testing for virulence plasmids. Your hospital lab serves as a sentinel to recognize and transfer suspicious specimens, while public health manages the complex logistics of secure specimen transport and federal notification requirements.

Know What to Ask, Not What to Know

Remember, your role is not to become an expert in select agent regulations or specimen transport requirements; these rules are complex, jurisdiction specific, and change frequently. Instead, focus on asking the right questions:

• What are the current notification requirements for this type of specimen?
• Who needs to be contacted beyond our local health department?
• What specific transport protocols do we need to follow?
• Are there any chain-of-custody requirements I should be aware of?
• What documentation will be needed for the transfer?

Public health maintains current knowledge of federal requirements and will coordinate any necessary notifications to state or federal agencies. Your expertise lies in clinical recognition and safe specimen management. Trust your public health partners to handle the regulatory maze while you focus on what you do best.

The IP as Public Health Coordinator and Staff Shield

As the potential bioterror event unfolds, your role expands beyond specimen management to crisis communication. Hospital staff will be anxious, potentially panicked, and looking to you and your leadership for guidance. Your joint communication strategy balances transparency with reassurance, providing facts and vital guidance to prevent unnecessary panic.

The key message to reinforce is the “standard precautions” mantra: While the specimen poses a potential threat and requires special handling, the patient is not contagious. Anthrax and Bcbva do not spread person-to-person, so standard precautions are sufficient for patient care. Staff who provided care for this patient are not at risk of infection through patient contact.²

Cultivating the Friday Evening Network

In infection prevention, a crisis rarely keeps office hours. Often, a suspected high-consequence pathogen surfaces as you are shutting down for the weekend. When these events invariably occur, the asset is not a policy you haven’t looked at in a year on a shared drive. It is your colleague at your local public health department, the one you have made a point of being on a first-name basis with. These connections must be maintained through regular check-ins because a relationship that exists only during an emergency is not a relationship at all.

Review and update your special and emerging pathogen policies annually, ensuring they address not only emerging infectious diseases but also emerging threats such as Bcbva. These policies should include clear escalation pathways, communication protocols, and specimen handling procedures. Most importantly, they should be accessible and familiar to all relevant staff.

Conclusion: Biosecurity Is a Team Sport

As phone calls and questions mount, it is easy to feel the weight of the world on your shoulders. But here is the most important truth an IP can remember: You are not expected to know everything.

Your role is not to have all the answers, but to be the person who knows which questions to ask and which phone numbers to call. In the world of special and emerging pathogens, public health is not just a regulatory body, they are your 24/7 support system. From coordinating the LRN to providing guidance on next steps, they are there to partner with you.

Emerging threats such as Bcbva prove that our enemies are evolving, using mimicry and deception to evade traditional detection methods. This is why our infection prevention protocols are “living” documents, flexible enough to adapt to new challenges while robust enough to ensure consistent, effective response.

Use this scenario to dust off your special and emerging pathogen policies. Are they living protocols that connect you to the resources designed to support you? By building these bridges now, you ensure that when the “crazy” happens, you are part of a coordinated, network-ready team to protect both your patients and your community.

The postal worker’s story may be hypothetical, but the threat is real. In an era where bioterror agents can disguise themselves as common contaminants and geopolitics are complicated, the IP’s role has never been more critical. You are the essential link between the bedside and the laboratory, the person who turns individual clinical suspicion into collective, decisive public health action.

Six hours later, that postal worker’s specimens are secure at the LRN laboratory, your staff is informed but not panicked, and public health has taken the lead on the investigation. This wasn’t luck; it was preparation meeting opportunity. The question isn’t whether you will face this scenario, but whether you will be ready when you do.

Resources

1. Identification of Bacillus cereus biovar anthracis. American Society for Microbiology. August 31, 2017. Accessed April 30, 2026. https://asm.org/guideline/identification-of-bacillus-cereus-biovar-anthracis
2. Anthrax (Bacillus spp) 2025 case definition. CDC. Updated September 23, 2024. Accessed April 30, 2026. https://ndc.services.cdc.gov/case-definitions/anthrax/
3. Anthrax: implementation guidance for clinicians. World Health Organization. August 26, 2025. Accessed April 30, 2026. https://www.who.int/publications/i/item/B09539